PLBIO(SZ:000403)2024-04-26 11:47Financial Performance - The company's operating revenue for 2023 was ¥2,328,723,280.44, a decrease of 3.18% compared to ¥2,405,188,425.37 in 2022[15]. - The net profit attributable to shareholders for 2023 was ¥612,111,043.76, an increase of 4.25% from ¥587,131,491.86 in 2022[15]. - The net profit after deducting non-recurring gains and losses was ¥564,595,832.55, up 9.08% from ¥517,574,851.42 in 2022[15]. - The net cash flow from operating activities increased by 29.53% to ¥679,006,330.60 in 2023 from ¥524,218,863.43 in 2022[15]. - The total assets at the end of 2023 were ¥8,630,474,084.53, an increase of 8.12% from ¥7,982,324,465.77 at the end of 2022[15]. - The net assets attributable to shareholders at the end of 2023 were ¥7,428,649,258.06, an increase of 8.17% from ¥6,867,524,210.96 at the end of 2022[15]. - The company reported a basic earnings per share of ¥0.8384 for 2023, up 4.34% from ¥0.8035 in 2022[15]. - The company achieved a net profit of RMB 75 million, RMB 120 million, RMB 180 million, and RMB 220 million for the years 2020, 2021, 2022, and 2023 respectively, as per the performance commitment made during the asset restructuring[179]. - The actual net profit for 2023 was RMB 28,364 million, achieving 128.93% of the promised net profit of RMB 22,000 million[182]. - Cumulative net profit from 2020 to 2023 reached RMB 65,325 million, exceeding the promised cumulative net profit of RMB 59,500 million by 109.79%[183]. Dividend Policy - The company plans to distribute a cash dividend of 2 RMB (including tax) for every 10 shares, based on a total of 730,818,180 shares[3]. - The cash dividend for 2023 represents 27.34% of the net profit attributable to shareholders of the listed company[132]. - The company has a policy to distribute at least 30% of the average distributable profit over the last three years if there are no major investment plans or cash expenditures[132]. - The company proposed a cash dividend of 0.80 CNY per 10 shares, totaling 58,611,415.36 CNY for the year 2022, with no stock dividends or capital reserve transfers[129]. - The total undistributed profit as of 2023 is 199,941,608.29 CNY, which will be carried forward to future years[131]. Market and Industry Overview - The global blood products market size was approximately $50 billion in 2023, expected to exceed $90 billion by 2030[21]. - The Chinese blood products market size was over ¥500 billion in 2023, projected to reach ¥950 billion by 2030[21]. - The company operates in a highly regulated industry with significant entry barriers, with only 28 qualified blood product manufacturers in China[22]. - The blood product market in China is expected to exceed 100 billion yuan in the future, driven by increasing demand and supportive government policies[28]. - The demand for blood products in China is projected to continue outpacing supply, with a long-term supply shortage expected due to stringent plasma collection policies[25]. Operational Capacity and Development - The company achieved a plasma collection volume of over 1,200 tons in 2023, positioning itself among the top tier of blood product companies in China[29]. - The company currently ranks third in the industry with a total of 38 plasma collection stations, following the top two competitors[29]. - The company has expanded its product offerings to a total of 11 types, with the potential to increase to 14, which is the maximum among domestic blood product companies[29]. - The company is actively pursuing strategic partnerships and acquisitions to enhance its market position and expand its plasma sourcing capabilities[29]. - The company is focusing on the development of recombinant products, particularly in the coagulation factor area, which will complement the blood product industry[24]. Research and Development - The company holds a total of 62 authorized patents, indicating strong research and development capabilities[37]. - The total R&D investment amounted to ¥93,741,734.60, representing 4.03% of operating revenue[52]. - The company is actively developing and selling intravenous cytomegalovirus immunoglobulin to prevent infections during organ transplants or immunosuppressive therapy[32]. - Over 10 new products are currently in development, with a focus on accelerating the clinical trial process for human fibrinogen and the next generation of intravenous immunoglobulin[76]. - The company is focused on enhancing its research and development capabilities to drive innovation in its product offerings[197]. Corporate Governance - The company maintains independence from its controlling shareholder in personnel, assets, finance, institutions, and business operations[89]. - The company has established a complete and independent production operation system with clear ownership of operating assets[89]. - The board of directors and supervisory board operate independently, ensuring effective checks and balances[89]. - The company has a standardized financial accounting system and operates independently without interference from the controlling shareholder[89]. - The company has implemented a structured remuneration system for its executives based on performance assessments[110]. Environmental Compliance - The company is not classified as a key pollutant discharge unit by environmental protection authorities, ensuring compliance with environmental regulations[150]. - The company has not experienced any pollution incidents or disputes during the reporting period, demonstrating adherence to environmental laws[151]. - The company strictly follows various environmental protection laws and standards, reinforcing its commitment to ecological responsibility[151]. - The company has established emergency response plans for environmental incidents, which have been filed with local ecological and environmental authorities[163]. - The company has implemented energy management practices aimed at reducing carbon emissions, achieving significant reductions in waste gas and wastewater discharge through new technologies and processes[165]. Strategic Partnerships and Market Expansion - The company is actively pursuing partnerships and collaborations to enhance its product offerings and market reach[102]. - The company signed an exclusive licensing and supply agreement with Hypera Pharma, a major player in Brazil's pharmaceutical market, indicating a strategic expansion into international markets[197]. - The company is expanding its market presence by signing exclusive licensing and supply agreements for overseas trade[194]. - The company plans to establish an investment fund in cooperation with professional investment institutions[194]. - The company is collaborating with Xinjiang Deyuan, indicating strategic partnerships for growth[194]. Employee and Management Structure - The total number of employees at the end of the reporting period is 2,426, with 2,426 receiving salaries[125]. - The company has 1,282 technical personnel, representing approximately 52.9% of the total workforce[125]. - The company has established a comprehensive training system focusing on regulatory, management, and skill development training[127]. - The management team includes professionals with backgrounds in auditing, investment, and human resources, enhancing the company's operational capabilities[105]. - The company has a diverse management team with extensive experience in various sectors, including biotechnology and finance[104].